KBC Group NV lifted its holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Free Report) by 30.5% during the fourth quarter, according to the company in its most recent filing with the SEC.

Agios Pharmaceuticals reported its fourth-quarter 2024 earnings, surpassing analysts' expectations with an earnings per share (EPS) of -$1.44 compared to the forecast of -$1.68. The company also ...

It is possible to love someone from afar for many years. This is how I felt about Sara Tindley. She was a local musician and I was a fan of her music. We lived in the same region, so I attended ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

It’s a major change of direction for Boston-based Agios, which has been concentrating on the oncology market since its inception in 2008, bringing the Bristol Myers Squibb-partnered Tibsovo ...

As one of the world’s biggest contributors to climate change, pharma is morally obliged to adapt its processes and operations – and doing so will open up new opportunities for growth.

Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo The U.S. Food and Drug Administration ...

Rocket Pharmaceuticals (RCKT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising ...

A notable potential in Russia and recovering Africa market further bolster optimism. India's pharma sector has seen remarkable growth in exports, with 99% target already being achieved before FY25, ...